Akari Therapeutics (AKTX)
1.15
-0.01 (-0.86%)
At close: Jan 14, 2025, 3:50 PM
1.13
-1.74%
After-hours Jan 14, 2025, 07:31 PM EST
undefined% (undefined)
| Bid | 0.99 |
| Market Cap | 13.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.28 |
| Volume | 13,127 |
| Avg. Volume (20D) | 57,740 |
| Open | 1.13 |
| Previous Close | 1.16 |
| Day's Range | 1.13 - 1.19 |
| 52-Week Range | 0.90 - 4.40 |
| Beta | undefined |
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous p...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 2014
Employees 6
Stock Exchange NASDAQ
Ticker Symbol AKTX
Website https://www.akaritx.com
9 months ago ·
Source
Akari Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
